Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Various biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been stu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	small cell lung cancer (SCLC) modified Glasgow prognostic score (mGPS) prognostic nutritional index (PNI) overall survival progression-free survival platinum-based combination chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2e944e4000f441b595ec242ac87fd8d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e944e4000f441b595ec242ac87fd8d6
record_format	dspace
spelling	oai:doaj.org-article:2e944e4000f441b595ec242ac87fd8d62021-12-02T04:41:43ZPretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer1179-2728https://doaj.org/article/2e944e4000f441b595ec242ac87fd8d62017-12-01T00:00:00Zhttps://www.dovepress.com/pretreatment-glasgow-prognostic-score-and-prognostic-nutritional-index-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Various biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been studied in advanced small cell lung cancer (SCLC). The modified Glasgow prognostic score (mGPS) is based on serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI) is a combination of serum albumin level and absolute lymphocyte count. This study aimed to evaluate the prognostic value of mGPS and PNI in SCLC.Methods: We retrospectively reviewed and calculated mGPS and PNI for patients with stage IIIB or IV SCLC who initiated platinum-based combination chemotherapy between November 2007 and June 2016. We compared overall survival (OS) and progression-free survival (PFS) between high and low groups of these two biomarkers. Univariate and multivariate Cox hazard analyses assessed the prognostic value of these biomarkers.Results: We reviewed 97 SCLC patients. The OS of patients with mGPS 0–1 and higher PNI was significantly longer than that of those with mGPS 2 and lower PNI. The PFS of mGPS 0–1 was significantly longer than that of mGPS 2, while there was no significant difference in PFS according to PNI. Multivariate analyses found mGPS 0–1 (hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.27–4.31, P<0.01) and higher PNI (HR 0.50, 95% CI 0.31–0.78, P<0.01) as prognostic factors for longer OS. However, neither biomarker was predictive of PFS.Conclusion: Our study was a small retrospective study; however, the data demonstrate that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment measurement of serum albumin, C-reactive protein, and absolute lymphocyte count. Keywords: small cell lung cancer, modified Glasgow prognostic score, prognostic nutritional index, overall survival, progression-free survivalMinami SOgata YIhara SYamamoto SKomuta KDove Medical Pressarticlesmall cell lung cancer (SCLC)modified Glasgow prognostic score (mGPS)prognostic nutritional index (PNI)overall survivalprogression-free survivalplatinum-based combination chemotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 249-257 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	small cell lung cancer (SCLC) modified Glasgow prognostic score (mGPS) prognostic nutritional index (PNI) overall survival progression-free survival platinum-based combination chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	small cell lung cancer (SCLC) modified Glasgow prognostic score (mGPS) prognostic nutritional index (PNI) overall survival progression-free survival platinum-based combination chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Minami S Ogata Y Ihara S Yamamoto S Komuta K Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
description	Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Various biomarkers have been shown to predict prognosis in various types of cancers. However, these biomarkers have not been studied in advanced small cell lung cancer (SCLC). The modified Glasgow prognostic score (mGPS) is based on serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI) is a combination of serum albumin level and absolute lymphocyte count. This study aimed to evaluate the prognostic value of mGPS and PNI in SCLC.Methods: We retrospectively reviewed and calculated mGPS and PNI for patients with stage IIIB or IV SCLC who initiated platinum-based combination chemotherapy between November 2007 and June 2016. We compared overall survival (OS) and progression-free survival (PFS) between high and low groups of these two biomarkers. Univariate and multivariate Cox hazard analyses assessed the prognostic value of these biomarkers.Results: We reviewed 97 SCLC patients. The OS of patients with mGPS 0–1 and higher PNI was significantly longer than that of those with mGPS 2 and lower PNI. The PFS of mGPS 0–1 was significantly longer than that of mGPS 2, while there was no significant difference in PFS according to PNI. Multivariate analyses found mGPS 0–1 (hazard ratio [HR] 2.34, 95% confidence interval [CI] 1.27–4.31, P<0.01) and higher PNI (HR 0.50, 95% CI 0.31–0.78, P<0.01) as prognostic factors for longer OS. However, neither biomarker was predictive of PFS.Conclusion: Our study was a small retrospective study; however, the data demonstrate that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment measurement of serum albumin, C-reactive protein, and absolute lymphocyte count. Keywords: small cell lung cancer, modified Glasgow prognostic score, prognostic nutritional index, overall survival, progression-free survival
format	article
author	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_facet	Minami S Ogata Y Ihara S Yamamoto S Komuta K
author_sort	Minami S
title	Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
title_short	Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
title_full	Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
title_fullStr	Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
title_full_unstemmed	Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
title_sort	pretreatment glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/2e944e4000f441b595ec242ac87fd8d6
work_keys_str_mv	AT minamis pretreatmentglasgowprognosticscoreandprognosticnutritionalindexpredictoverallsurvivalofpatientswithadvancedsmallcelllungcancer AT ogatay pretreatmentglasgowprognosticscoreandprognosticnutritionalindexpredictoverallsurvivalofpatientswithadvancedsmallcelllungcancer AT iharas pretreatmentglasgowprognosticscoreandprognosticnutritionalindexpredictoverallsurvivalofpatientswithadvancedsmallcelllungcancer AT yamamotos pretreatmentglasgowprognosticscoreandprognosticnutritionalindexpredictoverallsurvivalofpatientswithadvancedsmallcelllungcancer AT komutak pretreatmentglasgowprognosticscoreandprognosticnutritionalindexpredictoverallsurvivalofpatientswithadvancedsmallcelllungcancer
_version_	1718401115600453632

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Ejemplares similares